Please Share:: 
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
SUN PHARMA: Key takeaways
Cash on books will be used for acquisitions eventually—in US. However, for now SUN will
focus on (1) digesting Taro and (2) getting its three facilities under FDA regulatory scanner
back into compliance.
In India SUN operates with around 2,600 MRs covering 130,000 doctors. SUN expects to
grow at rates marginally higher than the market growth rate. SUN enjoys high MR
productivity at Rs0.7-0.8 mn/month, among the highest in the industry.
SUN will focus on 8-10 top emerging markets; however, will grow profitably rather than
chasing scale in these markets.
No plans to enter biologics as of now.
Novo has appealed the Prandin lower court ruling. SUN may evaluate launching at risk
once it gets final approval
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
SUN PHARMA: Key takeaways
Cash on books will be used for acquisitions eventually—in US. However, for now SUN will
focus on (1) digesting Taro and (2) getting its three facilities under FDA regulatory scanner
back into compliance.
In India SUN operates with around 2,600 MRs covering 130,000 doctors. SUN expects to
grow at rates marginally higher than the market growth rate. SUN enjoys high MR
productivity at Rs0.7-0.8 mn/month, among the highest in the industry.
SUN will focus on 8-10 top emerging markets; however, will grow profitably rather than
chasing scale in these markets.
No plans to enter biologics as of now.
Novo has appealed the Prandin lower court ruling. SUN may evaluate launching at risk
once it gets final approval
No comments:
Post a Comment